NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) today announced that it has finalized a previously reported agreement-in-principle to resolve all aspects of the investigations led by the United States Department of Justice (DOJ) and the United States Attorney’s Office for the District of Massachusetts that began in January 2004 relating to past marketing, sales, and other activities in connection with Celexa®, Lexapro®, and a formulation of Levothroid® that Forest ceased distributing in 2003. Forest previously disclosed reserves totaling $313 million plus interest in connection with these investigations. All of the payments described below are covered by such reserves and no additional charge to the company’s earnings will be recorded in connection with the final settlement.
